The FDA launched a PreCheck Pilot Program to speed up facility reviews. Eli Lilly and Regeneron made the cut. Six other companies too but nobody cares about them because they're not household names and retail traders can't spell their tickers without looking them up three times.
The program exists because the normal FDA approval process takes so long that by the time a facility gets cleared the equipment inside is already obsolete. Turns out you can just create a special fast lane for companies big enough to have lobbyists who know which wine the regulators prefer.
This will not affect your portfolio. Lilly stock will move based on weight loss drug sales and whatever Cramer said about diabetes yesterday. Regeneron will move based on literally nothing because half the market thinks it's a Transformer. The PreCheck program sounds important until you remember facility approval timelines mean absolutely nothing to the guy who bought calls expiring Friday because someone on WallStreetBets said the chart looked bullish.
Every biotech executive will now claim their manufacturing process deserves the fast lane. The FDA will nod politely and add them to a waitlist that moves slower than the regular process. That's how pilot programs work. You announce seven winners to generate headlines then quietly shelve the whole thing when nobody's looking.
Retail traders will read FDA initiative and assume this means their penny stock biotech just got approved for something. It did not. Your company is not in the pilot program. Your company will never be in the pilot program. Your company's facility is a rented warehouse in New Jersey with a broken autoclave and a guy named Derek who keeps using the centrifuge to separate his homemade kombucha.
The real innovation here is the FDA admitting their process was slow enough to need fixing while simultaneously refusing to fix it for anyone who matters to your brokerage account.
Photo by on Unsplash
Leave a Comment